A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD)
Latest Information Update: 07 Oct 2024
Price :
$35 *
At a glance
- Drugs Mirodenafil (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms Polaris-AD
- Sponsors AriBio
- 30 Sep 2024 According to an AriBio media release, two community practices that are part of the Adaptive Research network have begun patient enrollment and randomization in this trial. Noor Sachdev, MD and Perminder Bhatia, MD will serve as investigators with regulatory, finance, and clinical support for all study-related activities provided by Adaptive Research.
- 21 Jun 2024 According to an AriBio media release, the company entered into a strategic collaboration with Kentucky Clinical Trial Laboratory (KCTL) for the testing of cerebral spinal fluid (CSF) samples from this trial to accurately and efficiently aid in the diagnosis of Alzheimer's disease using the Lumipulse system from FujireBio.
- 31 May 2024 According to Neurophet media release, Neurophet has signed an agreement with AriBio, a developer of treatments for neurodegenerative disorders, to support and joint research in the global phase 3 clinical trial of AR1001, an oral Alzheimer's disease treatment.